Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is P&G’s pharma business for sale?

Executive Summary

A sale of Procter & Gamble's pharma business could fetch more than $1 billion, according to an estimate by one analyst. That's revenue P&G could reinvest in its core business areas, beauty and consumer health care. Reports that P&G's Rx business is up for sale began circulating the week of Feb. 2. Sources say the company has indeed hired Goldman Sachs to facilitate a sale of the business, although P&G dismissed the reports as "total speculation." News of a potential sale hardly comes as a surprise after P&G announced in December that the company was halting investment in pharmaceuticals and reducing headcount in its 2,900-person pharmaceutical workforce by 6 percent to 7 percent to focus on more profitable businesses, including oral care and consumer health care (1"The Pink Sheet," Dec. 22, 2008, p. 9). Potential buyers could include P&G's existing partners: Sanofi-Aventis on Actonel and Novartis on Enablex

You may also be interested in...

P&G Exits Drug R&D in Favor of Consumer Healthcare

Procter & Gamble is moving away from pharmaceuticals to focus on more profitable businesses, such as oral care and consumer healthcare

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts